Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Characterization of Congenital Sideroblastic Anemia Model Due to ABCB7 Defects: How Do Defects in Iron-Sulfur Cluster Metabolism Lead to Ring Sideroblast Formation?

Tohru Fujiwara, MD PhD, Chie Suzuki, Tetsuro Ochi, Koya Ono, MD, Kei Saito, Noriko Fukuhara, MD PhD, Yasushi Onishi, MD PhD, Hisayuki Yokoyama, MD PhD, Shinichi Fujimaki, Yukio Nakamura, MD PhD, Hideo Harigae, MD PhD

Blood (2019) 134 (Supplement_1): 2232.

https://doi.org/10.1182/blood-2019-123918

Published: 2019

Journal Articles

Deep Molecular Response Achieved By Second-Generation Tyrosine Kinase Inhibitors (TKIs) Can Lead to Stopping TKIs

Tetsuro Ochi, Taiichi Kyo, MD, Kayo Toishigawa, Takeshi Okatani, Ryota Imanaka, Kohei Kyo, Mitsuhiro Itagaki, Yuta Katayama, Koji Iwato, Hideki Asaoku

Blood (2015) 126 (23): 1594.

https://doi.org/10.1182/blood.V126.23.1594.1594

Published: 2015

Journal Articles

Therapy for AML with Myelodysplasia-Related Changes (AML-MRC)

Taiichi Kyo, MD, Kouhei Kyo, MD, Takeshi Okatani, MD, Tetsuro Ochi, MD, Kayo Toishigawa, Ryota Imanaka, MD, Yuta Katayama, MD PhD, Mitsuhiro Itagaki, MD

Blood (2015) 126 (23): 1340.

https://doi.org/10.1182/blood.V126.23.1340.1340

Published: 2015

Journal Articles

A High Incidence of Disseminated Intravascular Coagulation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia and Its Management

Ryota Imanaka, MD, Taiichi Kyo, MD, Kayo Toishigawa, MD, Tetsuro Ochi, MD, Takeshi Okatani, MD, Kouhei Kyo, MD, Mitsuhiro Itagaki, MD, Hisao Nagoshi, MD, Yuta Katayama, MD PhD, Koji Iwato, MD, Hideki Asaoku, MD

Blood (2015) 126 (23): 2500.

https://doi.org/10.1182/blood.V126.23.2500.2500

Published: 2015

Journal Articles

Title in Chemotherapy for Acute Myeloid Leukemia with High Leukocyte Counts.

Taiichi Kyo, MD, Ryota Imanaka, MD, Tetsuro Ochi, MD, Takeshi Okatani, MD, Kohei Kyo, MD, Mitsuhiro Itagaki, MD, Hisao Nagoshi, MD, Yuta Katayama, MD, Koji Iwato, MD, Hideki Asaoku, MD

Blood (2014) 124 (21): 5272.

https://doi.org/10.1182/blood.V124.21.5272.5272

Published: 2014

Journal Articles

Treatment of AML with Myelodysplasia Related Changes(AML-MRC) By Sequential Therapy of Azacitidine (AZA) and Intensive Chemotherapy

Taiichi Kyo, MD, Kouhei Kyo, MD, Kayo Toishikawa, MD, Ryota Imanaka, MD, Tetsuro Ochi, MD, Yuta Katayama, MD, Takeshi Okatani, MD, Mitsuhiro Itagaki, MD, Koji Iwato, MD, Hideki Asaoku, MD

Blood (2014) 124 (21): 5288.

https://doi.org/10.1182/blood.V124.21.5288.5288

Published: 2014

Journal Articles

Improvement Of The Efficacy Of Azacitidine At a Fixed Dosing Schedule Of 75mg/m 2 /Day For 5 Days, Followed By 21 Days Drug-Off In Higher Risk Myelodysplastic Syndromes

Taiichi Kyo, M.D., Kouhei Kyo, MD, Ryouta Imanaka, M.D., Mitsuhiro Itagaki, MD, Tetsuro Ochi, Takeshi Okatani, M.D., Koji Iwato, MD, Yuta Katayama, MD, PhD, Hideki Asaoku, M.D.

Blood (2013) 122 (21): 1571.

https://doi.org/10.1182/blood.V122.21.1571.1571

Published: 2013

Journal Articles

Voriconazole (VRCZ) Versus Itraconazole (ITCZ) As Antifungal Prophylaxis For Acute Myelogenus Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Patients In Induction Therapy, Prospective Randomized Study

Kouhei Kyo, M.D., Mitsuhiro Itagaki, MD, Taiichi Kyo, MD, Takeshi Okatani, M.D., Tetsuro Ochi, Yuta Katayama, MD, PhD, Ryouta Imanaka, M.D., Kouji Iwato, Hideki Asaoku, M.D.

Blood (2013) 122 (21): 3897.

https://doi.org/10.1182/blood.V122.21.3897.3897

Published: 2013

NARROW

Characterization of Congenital Sideroblastic Anemia Model Due to ABCB7 Defects: How Do Defects in Iron-Sulfur Cluster Metabolism Lead to Ring Sideroblast Formation?

Deep Molecular Response Achieved By Second-Generation Tyrosine Kinase Inhibitors (TKIs) Can Lead to Stopping TKIs

Therapy for AML with Myelodysplasia-Related Changes (AML-MRC)

A High Incidence of Disseminated Intravascular Coagulation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia and Its Management

Title in Chemotherapy for Acute Myeloid Leukemia with High Leukocyte Counts.

Treatment of AML with Myelodysplasia Related Changes(AML-MRC) By Sequential Therapy of Azacitidine (AZA) and Intensive Chemotherapy

Improvement Of The Efficacy Of Azacitidine At a Fixed Dosing Schedule Of 75mg/m 2 /Day For 5 Days, Followed By 21 Days Drug-Off In Higher Risk Myelodysplastic Syndromes

Voriconazole (VRCZ) Versus Itraconazole (ITCZ) As Antifungal Prophylaxis For Acute Myelogenus Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Patients In Induction Therapy, Prospective Randomized Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only